Trimethylamine-N-oxide as biomarker for the predisposition for weight gain and obesity
AssigneeNestec S.A.
InventorsFrancois-Pierre Martin, Claire L. Boulange, Ivan Montoliu Roura, Sebastiano Collino, Marc-Emmanuel Dumas, Elaine Holmes, Serge Andre Dominique Rezzi, Jeremy Nicholson, Sunil Kochhar
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be trimethylamine-N-oxide.
Claims14
A method of treating or preventing weight gain, the method comprising:
- determining the level of trimethylamine-N-oxide in a urine sample obtained from a subject, and
- comparing the subject's trimethylamine-N-oxide level to a predetermined reference value, wherein the predetermined reference value is an average trimethylamine-N-oxide level in urine from at least three healthy people with similar genetic background and age, relative to the subject, and
- providing a personalized diet to the subject that does not reduce caloric consumption if the level of trimethylamine-N-oxide in the subject's urine sample is decreased relative to the reference value.
A method of treating or preventing weight gain in a subject comprising the steps of:
- (1) obtaining a urine test sample from the subject;
- (2) detecting, in the urine test sample, the level of a first biomarker and the level of a second biomarker, wherein the first biomarker is trimethylamine-N-oxide and the second biomarker is selected from the group consisting of:
- hexanoylglycine, isovalerylglycine, leucine, isobutyrate, guanidoacetate, tartaric acid, hippuric acid and hydroxyphenylacetylglycine;
- (3) detecting, in a urine reference sample, the level of the first biomarker and the level of the second biomarker, wherein the urine reference sample is from one or more persons of the same gender, similar age and average health status;
- and
- (4) providing a personalized diet to the subject that does not reduce caloric consumption if:
- (i) the level of the first biomarker in the urine test sample is decreased relative to the urine reference sample, and
- (ii) the level of the second biomarker in the urine test sample is increased for hexanoylglycine, isovalerylglycine, leucine, isobutyrate, acetate, and/or decreased for guanidoacetate, tartaric acid, hippuric acid, and hydroxyphenylacetylglycine level in the urine test sample compared to the urine reference sample.
Dependencies are inferred from the claim text.